Initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction is related to platelet response to aspirin by Skorić, Boško et al.
  
 
    
 
Središnja medicinska knjižnica 
 
 
Škorić, B., Miličić, D., Lovrić, D., Gornik, I., Narančić Škorić, K., Sertić, J. (2008) 
Initial patency of the infarct-related artery in patients with acute ST elevation 
myocardial infarction is related to platelet response to aspirin. International journal of 
cardiology, [Epub ahead of print, Corrected Proof]. 
 
 
 
 
http://www.elsevier.com/locate/issn/0167-5273 
 
http://dx.doi.org/10.1016/j.ijcard.2008.11.031 
 
http://medlib.mef.hr/536  
 
 
 
 
 
 
 
 
 
 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/  
 
Initial Patency of the Infarct-related Artery in Patients with Acute ST Elevation 
Myocardial Infarction is Related to Platelet Response to Aspirin 
Bosko Skoric1, Davor Milicic1, Daniel Lovric1, Ivan Gornik2, Kristina Narancic Skoric3, Jadranka 
Sertic4 
1 Department of Cardiovascular Diseases, Zagreb University Hospital Center, Croatia 
2 Division of Intensive Care Medicine, University Hospital Center, Zagreb, Croatia 
3 University Hospital Merkur, Zagreb, Croatia 
4Clinical Institute of Laboratory Diagnosis, Zagreb University Hospital Center, Croatia 
 
Running title: Aspirin response and TIMI flow in AMI 
 
Corresponding author: 
Bosko Skoric, MD 
Department of Cardiovascular Diseases 
Zagreb University Hospital Center 
Kispaticeva 12, 10 000 Zagreb, Croatia 
Phone.: +385-91-5451-379; fax: +385-1-2312-247 
E-mail: bskoric3@yahoo.com 
 
Grant support for the conduction of this study was awarded by the Croatian Ministry of Science, 
Education and Sports (Project No. 1636). 
Abstract 
Introduction: A proportion of patients with acute ST-segment elevation myocardial infarction 
(STEMI) undergoing primary percutaneous coronary angiography (PCI) presents with patent 
infarct-related artery (IRA) on initial angiography. We tested the hypothesis that stronger platelet 
response to aspirin in these patients at admission might be associated with higher initial coronary 
flow in the IRA. Methods: Platelet response to aspirin was assessed with Multiplate ASPI-test 
before coronary angiography in 70 patients on previous aspirin treatment admitted for acute 
STEMI. Coronary flow on initial angiogram was evaluated quantitatively according to the 
Thrombolysis In Myocardial Infarction (TIMI) grading system. Depending on the degree of 
arachidonic acid (AA) induced platelet aggregation in ASPI-test, patients were stratified into four 
quartiles and compared according to initial TIMI flow. 
Results: When TIMI flow was compared according to quartiles of platelet aggregation in ASPI-
test, we have found significantly higher frequency of TIMI-2 and TIMI-3 flow among patients 
with low values of ASPI-test, i.e. with stronger aspirin response (P=0.014). None of the patients 
in the highest quartile of ASPI-test had TIMI flow of 2 or 3. 
Conclusions: Patients with stronger antiplatelet response to aspirin therapy in acute STEMI are 
more likely to present with spontaneous IRA recanalization.  
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Introduction 
Approximately 10-20% of patients with acute ST-segment elevation myocardial infarction 
STEMI present themselves with spontaneous coronary recanalization before angioplasty and the 
prognosis of these patients is significantly better in terms of smaller size of infarction, lower 
incidence of heart failure, and improved early as well as late survival when compared to patients 
with persistent occlusion [1]. Platelet-dependent thrombosis plays a crucial role in the occlusion 
of the infarct-related artery (IRA) in acute MI. It is possible that stronger platelet response to 
aspirin may influence the tendency to early spontaneous coronary reperfusion in a certain 
proportion of patients with acute STEMI. The aim of our study was to determine whether patients 
presenting with higher coronary flow in the IRA at the time of initial angiography differ from 
patients with persistent occlusion in terms of platelet response to aspirin. 
 
 
 
 
 
 
 
 
Material and methods 
Study population included 70 consecutive patients who underwent primary percutaneous 
coronary intervention (PCI) for acute STEMI. All patients were using 100 mg of aspirin daily for 
at least 7 days before admittance. The compliance to aspirin was assessed by interview. Blood 
samples were collected from antecubital vein before clopidogrel loading and angiography. 
Exclusion criteria were: previous treatment with clopidogrel, nonsteroidal anti-inflammatory 
drugs, heparin and GpIIbIIIa inhibitors, a history of bleeding disorders, platelet count ≤100x109/L, 
hematocrit ≤0.30 or renal failure (creatinine ≥140 µmol/L). All patients had given informed 
consent and the study protocol was approved by the local ethics committee. 
Platelet function test was done using Multiplate ASPI-test. This is the impedance-based «point-
of-care» test, where a resistance change between two electrodes immersed into the whole blood is 
determined after the addition of AA with its final concentration of 0.5 mM [2]. Aggregation is 
expressed in arbitrary units (U). Platelet reactivity was expressed as interquartile range. Aspirin 
resistance was defined by an AUC of >31 U (75th percentile of aggregation in ASPI-test from 
110 control patients with stable coronary artery disease taking daily 100 mg of aspirin). 
Coronary flow was evaluated quantitatively according to the Thrombolysis In Myocardial 
Infarction (TIMI) grading system by two independent interventional cardiologists at the core lab, 
blinded for aggregation measurements. TIMI-0 is related to complete occlusion of the IRA, 
TIMI-1 is related to some penetration of contrast beyond the point of obstruction but without 
perfusion of the distal coronary bed, TIMI-2 is related to perfusion of the entire IRA into the 
distal coronary bed but with delayed flow compared with a normal artery and TIMI-3 represents 
full perfusion of IRA with normal flow [3].  
Statistical Analysis: Statistical analyses were performed using the MedCalc v.7.2.1.0 statistical 
software. Categorical data are presented as absolute and relative frequencies, continuous 
variables as median with range. Non-parametric tests (Wilcoxon’s and Kruskal-Wallis as 
appropriate) tests were used for group comparisons of continuous variables; chi-squared test was 
used for comparisons of categorical variables. Spearman’s correlation was used for correlation 
analysis. Statistical significance was set at P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Patients were stratified into 4 quartiles based on the results of aggregation in ASPI-test: 1st 
quartile (Q1): 13.6–35.6, 2nd quartile (Q2): 35.6-55.9, 3rd quartile (Q3): 55.9–95.9 and 4th quartile 
(Q4): 95.9-180.7. There were no differences between quartiles with respect to: age, gender, 
previous myocardial infarction, diabetes mellitus, hypertension, hypercholesterolemia, smoking 
status, previous medical therapy, platelet count and mean platelet volume. On the initial 
angiography, TIMI-3 flow was observed in 4 patients (6%), TIMI-2 flow in 6 patients (9%), 
TIMI-1 flow in 12 patients (17%) and TIMI-0 flow in 48 (68%). There was no association of 
patients’ gender, age, diabetes mellitus, hypertension, hypercholesterolemia, smoking status, 
previous medical treatment, platelet count or mean platelet volume with initial TIMI flow.  
When compared initial TIMI flow in patients according to quartiles of aggregation in ASPI-test, 
we have found significantly higher frequency of TIMI-2 and 3 flow among those with low values 
of ASPI-test (P=0.014). None of the patients in the highest quartile of ASPI-test had TIMI flow 
of grade 2 or 3 (Table 1). The result was similar if we compared TIMI flow in patients with ASPI 
values that equaled optimal for our control population (ASPI<31): patients with optimal ASPI-
test had significantly higher proportion of TIMI-2 or 3 flow than the patients with suboptimal 
ASPI levels (P=0.004, Table 2). 
 
 
 
 
 
 
Table 1. Distribution of TIMI flow before intervention according to quartiles of patients’ 
ASPI test  
 
 1st quartile 2nd quartile 3rd quartile 4th quartile P value 
TIMI 0 11 (61.1%) 14 (82.4%) 9 (52.9%) 14 (77.8%) 
TIMI 1 1 (5.6%) 3 (17.6%)  4 (23.5%) 4 (22.2%) 
TIMI 2 5 (27.8%) 0 (0%) 1 (5.9%) 0 (0%) 
TIMI 3 1 (5.6%) 0 (0%) 3 (17.6%) 0 (0%) 
0.014 
total patients 18 (100%) 17 (100%) 17 (100%) 18 (100%)  
 
TIMI = Thrombolysis In Myocardial Infarction score 
 
Table 2. Difference of TIMI flow before intervention in patients with optimal and 
suboptimal ASPI test 
 
 ASPI ≤ 31 (optimal) ASPI > 31 (suboptimal)  
TIMI 0 7 (58.3%) 41 (70.2%) 
TIMI 1 0 (0%) 12 (20.1%) 
TIMI 2 4 (33.3%) 2 (3.5%) 
TIMI 3 1 (8.3%) 3 (5.3%) 
P=0.004 
total patients 12 (100%) 58 (100%)  
 
TIMI = Thrombolysis In Myocardial Infarction score 
 
 
 
 Discussion 
The benefit from aspirin in patients with acute MI has already been ascertained. However it is not 
known whether this is due to a higher rate of early spontaneous IRA recanalisation. The influence 
of platelets physiology on early coronary patency has been previously reported. Soluble platelet 
glycoprotein V as a marker of stronger platelet activation was found to be higher in plasma of 
patients with acute STEMI and persistent occlusion at initial angiography when compared to 
those with spontaneous recanalization [4]. Maden et al found that lower admission mean platelet 
volume was an independent predictor of IRA patency in patients with acute STEMI [5], although 
we didn’t confirm this in our study. Finally, aspirin effect is heterogeneous and a part of treated 
patients have suboptimal antiplatelet response, the so called aspirin resistance. There is a 
substantial body of evidence for its unfavorable role in the development of adverse clinical 
cardiovascular events [6]. 
Our study is the first to examine the relation of platelet aspirin response to the patency of IRA 
before primary angioplasty in acute STEMI. We had only 6% of patients with initial TIMI-3 flow 
which is much lower then 16% reported by Stone et al [1]. This can be explained by their 
definition of TIMI-3 flow, where “complete filling of the distal vessel by the third cardiac cycle” 
overestimates the proportion of these patients when compared to the original TIMI definition that 
was used in our study [7].  
Our results indicate that patients with stronger response to aspirin as assessed by AA induced 
aggregation in ASPI-test have significantly higher initial coronary flow when compared to those 
with suboptimal platelet response. The limitations of our study are the small size of the study 
population and lack of objective method, other than patient interview, to ascertain previous usage 
of aspirin. 
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